Therefore, at least in the case of pancreatic cancer where the tumors appear to be highly dependent on energy from autophagy especially when KRAS or its downstream effectors are inhibited, combination of KRB-456 with autophagy inhibitors may also prove to be efficacious. Here, KRAS is linked to familial pancreatic carcinoma.